News #ECTRIMS2016 – Immune Cells Linked to Autoimmunity Found in MS Patients’ Gut #ECTRIMS2016 – Immune Cells Linked to Autoimmunity Found in MS Patients’ Gut by Patricia Silva, PhD | September 15, 2016 Share this article: Share article via email Copy article link Immune cells, believed to drive autoimmunity, are selectively increased in the gut of patients with multiple sclerosis (MS), along with lower numbers of cells controlling inflammation, suggesting that immune processes in the gut impact MS disease mechanisms. The study, āThe role of gut immunity in multiple sclerosis patients,ā was presented at the Young Scientific Investigatorsā Session 2 of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 CongressĀ Sept. 14-17 in London. Today, few researchers doubt that gut immune processes impact immune mechanisms in the rest of the body, and may contribute to autoimmunity. A common theory is that environmental factors, such as diet and microbes, increase the risk of developing an autoimmune disease in people who carry a genetic risk by changing intestinal immunity. Many studies have been performed in animal models of MS concerning the role of gut microbiota, but the research team from San Raffaele Hospital in Italy chose to investigate patients directly. The team recruited 23 relapsing-remitting MS patients and 16 control individuals who underwent anĀ endoscopy for diagnostic purposes. The team analyzed the immune cells found in the gut mucosa and in the blood of these individuals. None of theĀ MS patients had been treated with corticosteroids inĀ the previous six months, and antibiotics in the previous four weeks, as these treatments are known to impact the gut microbiota. ResearchersĀ found Th17 cells, an immune cell type believed to be involved in MS mechanisms in the intestines of MS patients but not in their blood. Also, Th22 cells were found only in the gut. MS patients also had more activated Th17 cells and less anti-inflammatory cells known as regulatory T-cells (Tregs) in their intestinal mucosa, compared to control individuals. “Our data suggest that there is a selective activation of Th17 cells in the intestinal mucosa of MS patients. These findings validate previous reports in pre-clinical models of MS and provide the first evidence that gut immunity modulate MS pathogenesis in humans,”Ā the research team wrote in their ECTRIMS abstract. “Our next goal is to determine how environmental factors such as diet can modulate MS pathogenesis through alterations of gut microbiota composition and intestinal immunity.” Investigations on how processes in the intestines can impact immunity are soaring. Earlier this year, researchers showed that MS patients have different gut microbes than healthy people. Another study showed that the gut inhabitants of MS patients tend to be of the kind that trigger inflammation. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags gut bacteria, inflammation, microbiota, Th17 cells, Tregs
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year